BRY805 / Zhejiang Hisun Pharmaceutical - LARVOL DELTA

A Study of BRY805 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=13 | Terminated | Sponsor: BioRay Pharmaceutical Co., Ltd. | N=30 ➔ 13 | Trial completion date: Sep 2027 ➔ Jul 2025 | Not yet recruiting ➔ Terminated | Trial primary completion date: May 2027 ➔ May 2025; Adjustment of the company's R&D strategy

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Oncology • Solid Tumor

Generation, Characterization, and Preclinical Studies of a Novel NKG2A-Targeted Antibody BRY805 for Cancer Immunotherapy. (PubMed, Antibodies (Basel)) - "Furthermore, BRY805 exhibited synergistic antitumor activity when combined with PD-L1 monoclonal antibodies. In a mouse xenograft model, BRY805 showed superior tumor control relative to monalizumab and demonstrated a favorable safety profile in non-human primate studies."

Journal • Preclinical • Oncology • CD8 • HLA-E • KLRC1 • KLRD1

A Study of BRY805 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: BioRay Pharmaceutical Co., Ltd.

Metastases • New P1 trial • Oncology • Solid Tumor